Background
Once evidence‑based medicine validates the efficacy of cerebral cytoprotection and confirms that its initiation ought to be brought forward to the hyper‑acute phase, the subsequent core challenge lies in guaranteeing that this therapeutic strategy lasts long enough to cover the full pathological injury cycle of ischaemic stroke. Cerebrocytoprotective treatment should not merely rely on hyper‑early initiation; a clinical pathway for adequate‑duration management must also be established concurrently. On this subject, Professor Zhang Yongwei from the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) has presented an ischaemic‑stroke management strategy characterised by "early initiation and full‑course‑duration management".
Expert Profile

Yongwei Zhang, MD
·Professor, Chief Physician The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
·Deputy Director of the Cerebrovascular Disease Center and Deputy Director of the Clinical Research Ward, Shanghai Changhai Hospital.
·Deputy Secretary-General, China Stroke Specialty Alliance;
·Standing Committee Member & Youth Standing Director, Critical Cerebrovascular Disease Branch, Chinese Stroke Society
·Member, Neurocritical Care Collaborative Group, Neurology Branch of Chinese Medical Association; Deputy Group Leader, Cerebral Artery Stenosis and Occlusion Group, Neurointerventional Physicians Branch, Chinese Medical Doctor Association
·Member, Neurocritical Care Group, Neurology Physicians Branch, Chinese Medical Doctor Association; Standing Committee Member, Severe Brain Injury Committee, China Association for the Promotion of Human Health Science and Technology
·Standing Committee Member, Nerve Injury and Repair Committee, Chinese Research Hospital Association
·Member, Stroke Prevention and Control Expert Committee, Chinese Preventive Medicine Association
·Member, Stroke Specialized Branch, Shanghai Medical Association
·Member, Neurointervention Committee, Shanghai Medical Doctor Association
·Youth Committee Member & Member of Cerebrovascular Intervention Group, Neurology Committee of the Chinese PLA.
The Treatment Window Has Grown
For decades, ‘time is brain’ has anchored acute ischemic stroke care, driving public health systems to shorten door-to-needle time and expand access to reperfusion therapies. Yet ischemic injury does not stop at reperfusion. A growing body of preclinical and translational work suggests that the molecular cascades triggered by ischemia continue to evolve across the first two weeks, raising an increasingly practical question: should cytoprotective therapy, like reperfusion, also be administered early — and continued long enough to cover the full acute phase?
Pathology Continues Long After Reperfusion
Following focal cerebral ischemia, four overlapping processes drive tissue injury: excitotoxicity, oxidative stress, neuroinflammation with blood-brain barrier (BBB) disruption, and cell death signaling (Salaudeen et al., 2024). Their temporal profiles differ.
Cellular and Vascular Trajectories
· Microglia: Pro-inflammatory M1-polarized microglia emerge around day 3 after ischemia and peak near day 14, releasing IL-1β, IL-6, and TNF-α (Hu et al., 2012).
· Astrocytes: Pro-inflammatory A1 astrocytes accumulate gradually through the mid-to-late acute phase and reach maximum density during the subacute period (Liddelow et al., 2017).
· Blood-brain barrier: Neuroinflammation degrades tight junctions and increases permeability in the acute phase. In the subacute phase, nascent vasculature begins to form but remains functionally immature, so permeability abnormalities persist (Guo et al., 2025; Lakhan et al., 2013).
If a cytoprotective agent is initiated in the hyperacute window but stopped before the inflammation peak and BBB remodeling phase, cumulative tissue protection may be limited.
What the Guidelines Actually Recommend
The Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023) define the acute phase of ischemic stroke as the first two weeks after onset and call for 14-day acute care to cover excitotoxicity, oxidative stress, the inflammation peak, and BBB repair. The guidelines also set a door-to-needle time (DNT) target within 60 minutes and emphasize stroke units and mobile stroke units to minimize treatment delay.
In routine practice, however, the 14-day course is often truncated. According to the 2024 China Health Statistics Yearbook, the average length of stay for acute ischemic stroke in China is approximately 10 days, meaning most patients are discharged before completing the guideline-defined acute period.
“The 14-day acute phase is not realistically completed during a typical hospitalization,” said Professor Yongwei Zhang of Shanghai Changhai Hospital, First Affiliated Hospital of Naval Medical University. “How to deliver full-course cytoprotection across the entire care continuum is what we need to focus on next.”
Clinical Evidence for a 14-Day Course
The most-cited Chinese clinical evidence for 14-day cytoprotection comes from the TASTE program of edaravone-dexborneol, a free-radical-scavenging combination.
Key Trials and Real-World Cohort
· TASTE (Xu et al., Stroke, 2021): A phase III, randomized, double-blind, comparative trial showed that 14-day edaravone-dexborneol significantly improved the proportion of patients achieving functional independence (mRS ≤1) at 90 days compared with edaravone alone.
· TASTE-SL (Fu et al., JAMA Neurology, 2024): A randomized, double-blind trial of the sublingual tablet formulation, also given for 14 days, reported a 90-day mRS ≤1 rate of 64.4%, roughly 10 percentage points higher than control, supporting non-inferiority of the sublingual formulation to the intravenous concentrate.
· EXPAND (Ma et al., Neurology, 2025): A multicenter, prospective cohort study across 18 provinces and 72 stroke centers in China enrolled 4,684 patients receiving edaravone-dexborneol in routine practice. Earlier initiation was associated with a higher likelihood of good functional outcome — adjusted odds ratio (aOR) 1.55 (95% CI 1.15-2.09) in the overall early-use group and 1.61 (95% CI 1.20-2.15) in the subgroup that also received reperfusion therapy.
“These findings are consistent with a dose-time-dependent relationship, in which treatment duration itself appears to be a key variable shaping clinical benefit,” Zhang said. “Starting therapy without guaranteeing an adequate course may not fully realize its potential value.”
Bridging Inpatient and Outpatient Cytoprotection
The structural gap between guideline-defined 14-day treatment and a 10-day average hospital stay creates a need for an outpatient bridge. Two pharmacologic properties of the sublingual edaravone-dexborneol tablet are relevant.
Pharmacokinetic and Practical Considerations
· Pharmacokinetics: The sublingual formulation is absorbed through the sublingual mucosal plexus and reportedly dissolves within about 5 minutes, bypassing first-pass hepatic metabolism and remaining usable in patients with dysphagia or difficult venous access.
· Comparable exposure: A comparative analysis of two phase III studies suggested similar clinical efficacy and pharmacokinetic profile between the sublingual tablet and the intravenous concentrate, supporting direct transition from IV to sublingual dosing without an expected drop in plasma exposure (Xie et al., Frontiers in Pharmacology, 2025).
A practical protocol now used at some Chinese stroke centers pairs intravenous edaravone-dexborneol during hospitalization with the sublingual tablet after discharge, aiming to complete the full 14-day acute course. Zhang noted that ongoing studies are also exploring whether longer treatment durations could further extend clinical benefit, though such regimens have not yet been validated in randomized trials.
Limitations and Open Questions
Several caveats apply. The EXPAND study is observational, so residual confounding — including treatment-selection bias, stroke severity, and center-level practice variation — cannot be excluded. The 14-day duration used in TASTE and TASTE-SL was empirically selected to cover the acute phase; whether longer courses further improve outcomes is being explored but remains unproven. Comparator choices in some Chinese trials (edaravone alone, rather than placebo) also limit direct comparison with international stroke trials. Finally, edaravone-dexborneol is currently approved mainly in China, and generalization to non-Chinese populations and health systems has not been established.
Larger randomized studies, head-to-head comparisons with intravenous thrombolysis or mechanical thrombectomy adjuncts, and longer-duration protocols are still needed to determine how early initiation and full-course delivery should be operationalized in routine stroke care.
References
1. Salaudeen MA, Bello N, Danraka RN, et al. Understanding the pathophysiology of ischemic stroke: the basis of current therapies and opportunity for new ones. Biomolecules. 2024;14(3).
2. Hu X, Li P, Guo Y, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43(11):3063-3070.
3. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481-487.
4. Guo P, Li H, Zhang X, et al. Matrix metalloproteinase-9 in hemorrhagic transformation after acute ischemic stroke (Review). Mol Med Rep. 2025;32(2).
5. Lakhan SE, Kirchgessner A, Tepper D, et al. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol. 2013;4:32.
6. Chinese Society of Neurology, Chinese Stroke Association. Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2023. Chin J Neurol. 2024;57(6):523-559.
7. National Health Commission of the People’s Republic of China. 2024 China Health Statistics Yearbook.
8. Xu J, Wang A, Meng X, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial. Stroke. 2021;52(3):772-780.
9. Fu Y, Wang A, Tang R, et al. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial. JAMA Neurol. 2024;81(4):319-326.
10. Ma G, Mo R, Yao X, et al. Clinical and safety outcomes of edaravone dexborneol in acute ischemic stroke: a multicenter, prospective, cohort study. Neurology. 2025;105(4):e213949.
11. Chinese Stroke Association. Stroke education resource. Available at: https://www.chinastroke.net/a565.html
12. Xie F, Lu Y, Yang Z, et al. Cost-effectiveness of edaravone dexborneol sublingual tablet versus concentrated solution for injection for the treatment of acute ischemic stroke in China. Front Pharmacol. 2025;16:1661581.